These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20078597)

  • 1. Redefining personalized medicine in the postgenomic era: developing bladder cancer therapeutics with proteomics.
    Blanchet KD
    BJU Int; 2010 Jan; 105(2):i-iii. PubMed ID: 20078597
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary bladder tumor markers.
    Lokeshwar VB; Selzer MG
    Urol Oncol; 2006; 24(6):528-37. PubMed ID: 17138134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network views for personalized medicine.
    Vlahou A
    Proteomics Clin Appl; 2013 Jun; 7(5-6):384-7. PubMed ID: 23532915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can a point-of-care urine protein assay monitor bladder cancer recurrence?
    O'donnell MA
    Nat Clin Pract Oncol; 2006 Sep; 3(9):482-3. PubMed ID: 16955086
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular markers in bladder cancer.
    Shariat SF; Karam JA; Lerner SP
    Curr Opin Urol; 2008 Jan; 18(1):1-8. PubMed ID: 18090481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of 2D-DIGE in cancer proteomics toward personalized medicine.
    Kondo T; Hirohashi S
    Methods Mol Biol; 2009; 577():135-54. PubMed ID: 19718514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of urinary biomarkers in early bladder cancer diagnosis.
    Lam T; Nabi G
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.
    Kawanishi H; Matsui Y; Ito M; Watanabe J; Takahashi T; Nishizawa K; Nishiyama H; Kamoto T; Mikami Y; Tanaka Y; Jung G; Akiyama H; Nobumasa H; Guilford P; Reeve A; Okuno Y; Tsujimoto G; Nakamura E; Ogawa O
    Clin Cancer Res; 2008 May; 14(9):2579-87. PubMed ID: 18451219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder squamous cell carcinoma biomarkers derived from proteomics.
    Celis JE; Wolf H; Ostergaard M
    Electrophoresis; 2000 Jun; 21(11):2115-21. PubMed ID: 10892722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors of infiltrating tumors of the bladder].
    Maulard-Durdux C; Housset M
    Cancer Radiother; 1998 Apr; 2 Suppl 1():5s-11s. PubMed ID: 9749069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel blood biomarkers of human urinary bladder cancer.
    Osman I; Bajorin DF; Sun TT; Zhong H; Douglas D; Scattergood J; Zheng R; Han M; Marshall KW; Liew CC
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3374-80. PubMed ID: 16740760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers in bladder cancer: a critical appraisal.
    Konety BR
    Urol Oncol; 2006; 24(4):326-37. PubMed ID: 16818187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene signatures for risk-adapted treatment of bladder cancer.
    Ørntoft TF; Dyrskjøt L
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):166-74. PubMed ID: 18815931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
    Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
    Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The "proteomics forum". Interdisciplinary proteome research by the Essen University Clinic].
    Goebell PJ; Rübben H; Müller G; Rettenmeier AW
    Urologe A; 2007 Sep; 46(9):1157-60. PubMed ID: 17605121
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in bladder cancer diagnostics.
    Sanchez-Carbayo M
    Clin Biochem; 2004 Jul; 37(7):562-71. PubMed ID: 15234237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary markers in bladder cancer.
    Vrooman OP; Witjes JA
    Eur Urol; 2008 May; 53(5):909-16. PubMed ID: 18162285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer proteomics: many technologies, one goal.
    Conrads TP; Hood BL; Petricoin EF; Liotta LA; Veenstra TD
    Expert Rev Proteomics; 2005 Oct; 2(5):693-703. PubMed ID: 16209649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.